{
    "organizations": [],
    "uuid": "86a70571a32765e36534b5c811c77680c0ea66f9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-acorda-therapeutics-q4-adj-shr-061/brief-acorda-therapeutics-q4-adj-shr-0-61-idUSL8N1Q53XZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Acorda Therapeutics Q4 Adj Shr $0.61",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 15 (Reuters) - Acorda Therapeutics Inc:\n* Q4 REVENUE $188.4 MILLION * Q4 NON-GAAP EARNINGS PER SHARE $0.61\n* Q4 GAAP LOSS PER SHARE $3.70 * AMPYRA NET REVENUE IS EXPECTED TO BE $330 MILLION TO $350 MILLION IN 2018\n* RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2018 ARE EXPECTED TO BE $100 MILLION TO $110 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-15T19:29:00.000+02:00",
    "crawled": "2018-02-16T17:08:23.029+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "acorda",
        "therapeutic",
        "inc",
        "q4",
        "revenue",
        "million",
        "q4",
        "earnings",
        "per",
        "share",
        "q4",
        "gaap",
        "loss",
        "per",
        "share",
        "ampyra",
        "net",
        "revenue",
        "expected",
        "million",
        "million",
        "research",
        "development",
        "expense",
        "full",
        "year",
        "expected",
        "million",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}